No Data
No Data
No Data
No Data
No Data
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Co
Vor BiopharmaMay 3 00:00 ET
Express News | Vor Biopharma Inc - on April 30, Board Increased Size of Board From Six to Seven Members
ReutersMay 2 16:47 ET
Vor Biopharma Welcomes Oncology Expert to Board of Directors
TipRanksMay 2 16:27 ET
Press Release: Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to Its Board of Directors
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR),
Dow JonesMay 2 16:01 ET
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to Its Board of Directors
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board o
Vor BiopharmaMay 2 00:00 ET
Express News | Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Moomoo 24/7Apr 23 13:24 ET
No Data
No Data